Halozyme Therapeutics, Inc. announced that Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration for Herceptin Hylecta™, a subcutaneous fixed-dose combination of trastuzumab and hyaluronidase-oysk.
February 28, 2019
· 4 min read